BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 125 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $134,000 | -60.8% | 10,677 | -49.2% | 0.02% | -40.5% |
| Q1 2022 | $342,000 | -82.1% | 21,035 | -91.8% | 0.04% | -76.1% |
| Q4 2020 | $1,908,000 | +418.5% | 256,210 | +231.4% | 0.16% | +307.9% |
| Q2 2020 | $368,000 | +332.9% | 77,301 | +212.9% | 0.04% | +1166.7% |
| Q4 2019 | $85,000 | +3.7% | 24,704 | -14.7% | 0.00% | -25.0% |
| Q3 2019 | $82,000 | -57.3% | 28,949 | +21.6% | 0.00% | -60.0% |
| Q4 2018 | $192,000 | -55.1% | 23,800 | -68.2% | 0.01% | +11.1% |
| Q2 2018 | $428,000 | +46.1% | 74,800 | -27.9% | 0.01% | -35.7% |
| Q1 2016 | $293,000 | +35.0% | 103,800 | +443.5% | 0.01% | -12.5% |
| Q3 2015 | $217,000 | -15.9% | 19,100 | +10.4% | 0.02% | -59.0% |
| Q2 2015 | $258,000 | +113.2% | 17,300 | +50.4% | 0.04% | +550.0% |
| Q1 2014 | $121,000 | – | 11,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |